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The administration of hydroxyurea (3 x 10-4M) and cytosine arabinoside (lo-‘M) greatly induces the expression of the vimentin gene in human 
promonocytic leukemia U-937 cells. The induction takes place at both the mRNA and protein levels, as demonstrated by Northern blot, immuno- 
blot and immunofluorescence assays. On the contrary, the drugs inhibit the expression of c-myc and ornithine decarboxylase, and do not modify 
significantly the expression of /I-actin. Since hydroxyurea nd cytosine arabinoside trigger the phenotypic differentiation of U-937 cells, as demon- 
strated by the induction of the differentiation-specific CD1 lb and CD1 lc antigens, it is concluded that vimentin expression might be implicated 
in the maturation of these cells. 
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1. INTRODUCTION 
One of the goals in the studies of cell differentiation 
consists in the characterization of the genes implicated 
in this process. It has been suggested that vimentin, the 
major intermediate-size filament protein in cells from 
mesenchymal origin, might be involved in the matura- 
tion of hemopoietic cells. Much of the evidence suppor- 
ting this idea is given by the observation that the phor- 
bol ester TPA, a potent maturation inducer of cultured 
myeloid cells, stimulates at the same time vimentin 
expression [ 1,2]. This observation must be considered 
with caution since TPA, a protein kinase C activator, is 
capable per se of stimulating many biochemical func- 
tions, including the expression of several genes, ir- 
respective of the cell species and of the final conse- 
quence for the cell phenotype (see [3] for review). For 
instance, it has been shown that TPA stimulates vimen- 
tin synthesis in chicken embryo fibroblasts, but this is a 
non-differentiating cell line [4]. Also, TPA stimulates 
the expression of the ODC gene in human myeloid cells 
[5], whereas ODC does not appear to be directly im- 
plicated in the differentiation of these cells [5,6]. Thus, 
the establishment of a clear correlation between cell dif- 
ferentiation and the expression of vimentin (and, in 
general, of any other gene) may require the examination 
of the effects of other inducers with different action 
mechanisms at the molecular level. 
In this work we study the action of two S-phase in- 
hibitors, HU and ara-C, on U-937 cells, a human pro- 
monocytic leukemia cell line. We observe that HU and 
ara-C efficiently trigger the phenotypic differentiation 
of these cells. At the same time, the drugs greatly induce 
the expression of vimentin, both at the mRNA and pro- 
tein levels. 
2. MATERIALS AND METHODS 
2.1. Cell culture and drug treatment 
U-937 cells were grown in RPMI-1640 medium supplemented with 
10% heat-inactivated fetal calf serum, 5 mM Hepes buffer, 0.2% 
(w/v) sodium bicarbonate, in humidified 5% COZ atmosphere at 
37°C. Cells were seeded in RIO-mm plastic dishes and maintained in 
continuous logarithmic growth by passing them every 2-3 days. TPA, 
HU and ara-C were obtained from Sigma (St. Louis, MO). TPA was 
dissolved in DMSO at 1.5 x lo- 3 M. HU and ara-C were dissolved in 
RPM1 at 3 x lo-* M and 10-j M, respectively. The drugs were ap- 
plied at final concentrations of 3 x lo- * M TPA, 3 x 10m4 M HU and 
lo-’ M ara-C. 
2.2. Immunofiuorescence and flow cytometry 
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To detect the expression of surface antigens, indirect im- 
munofluorescence determinations were carried out using the MAbs 
Bear 1 (anti-CD1 lb) [7], HCI/l (anti-CD1 lc) 181, and FG1/6 (specific 
for the TfR) [9]. The cells were labelled with the antibodies for 30 min 
at 4°C. After two washes with RPM1 medium, FITC-labelled sheep 
anti-mouse IgG (Amersham, England) was added and the incubation 
followed for an additional period of 30 min at 4°C. After washing the 
cells twice with RPM1 medium, their fluorescence was estimated by 
flow cytometry with an EPICS-flow cytometer, with an argon laser 
operated at 200 mV and excitation wavelength at 488 nm. 
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To measure the cytoskeleton-associated vimentin, cells were fixed 
for 5 min at room temperature with 3.7010 formaldehyde in a buffer 
containing 2 mM MgCl2, mM EGTA and 100 mM PIPES, pH 6.8, 
and then permeabilized for 5 min at room temperature with 0.2% 
(v/v) Triton X-100, 3.7% (v/v) fo~aldehyde, in the same buffer. 
After two washes with RPM1 medium, the cells were incubated with 
a mouse monoclonal anti-vimentin antibody (Amersham), washed 
twice with RPM1 medium and incubated with FITC-labelled sheep 
anti-mouse IgG for 45 min at 37°C. After two washes with RPM1 
medium, the cell fluorescence was estimated by flow c~ometry, as 
above. 
2.3. RNA blot assays 
Total cytoplasmic RNA was prepared as described in a previous 
work [IO]. RNA samples (15 cg per lane) were denatured, then elec- 
trophoresed in 1.1% (w/v) agarose-formaldehyde g ls [l l] and blot- 
ted onto a nylon membrane. RNA blots were prehybridized, hybridiz- 
ed with excess “P-1abelled probes, washed under highly stringent con- 
ditions [12], and finally autora~ographed. The probes used were: the 
1.1 kb human vimentin-sp~i~c X&o1 fragment of L3ArA plasmid 121; 
the 1.5 kb CloI-EcoRI fragment of pMC413rc plasmid, which con- 
tains the 3rd exon human c-myc [13]; the 1.5 kb human OCD-specific 
XhoI fragment of OB-821 plasmid [5], and the 0.66 kb chicken@- 
a&n-specific @rrI-BglII fragment of pAL41 plasmid [14]. The 
fragments were labelled to 1.0-l .S x lo9 cpm/@g of DNA with (cY-~‘P) 
dCTP (3000 Ci/mmol, Amersham, UK) by random hexanucleotide 
priming 1151. 
2.4. Immu~obIot assays 
Cells were washed once with PBS and lysed in 62.5 mM Tris-HCl, 
pH 6.8, containing 2% (w/v) SDS, 5% (v/v),&mercaptoethanol, and 
10% (v/v) glycerol. After boiling for 2 min at PVC, aliquots cor- 
responding to I50 pg of total protein were separated in SDS- 
polyacrylamide (iO%, w/v) slab gels, according to the Laemmli pro- 
cedure 1161. Electrophoretic blotting onto nitrocelhtlose and im- 
munological detection of proteins were carried out essentially as 
described by Towbin et al. [17], using mouse monoclonal anti- 
vimentin and horseradish peroxidas~conjugated rabbit anti-mouse 
IgG (Dakopatts, Denmark) as the first and the second antibodies, 
respectively, and developing with cu-chloronapthol as substrate. 
3. RESULTS 
3.1. Expression of cell surface antigens 
The capability of HU and ara-C to induce the dif- 
ferentiation of U-937 cells was assessed by measuring 
the surface expression of several antigens, namely 
CD1 lb, CD1 lc and TfR. As a control, we also included 
TPA, a potent maturation-inducing agent. The concen- 
trationsof3x10-4MHU, 10-7Mara-Cand3X10-8 
M TPA were adopted on the ground of their earlier use 
in studies of differentiation in human myeloid cells 
poo 
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[5,18,19]. Previous studies had determined that CDllb 
and CD1 lc are differentiation-specific antigens [7,8]. 
On the contrary, TfR is expressed at high levels in 
rapidly growing myeloid cells, and decays during dif- 
ferentiation 191. The results obtained are summarized in 
fig. 1. Both HU and ara-C greatly induced the expres- 
sion of CD1 lb and CD1 lc, the percentage of cells ex- 
pressing these antigens at the 3rd day of treatment being 
comparable to that obtained with TPA. In addition, the 
S-phase inhibitors provoked a decrease in the number 
of cells expressing TfR, although to a lower extent than 
with the phorbol ester. These results suggest hat HU 
and ara-C induce the phenotypic diferentiation of U937 
cells. 
3.2. r~d~~tio~ of vimentin &WA levels 
To analyze possible changes in the cellular content of 
vimentin RNA, Northern blot analyses were carried out 
using total cytoplasmic RNA extracted from either un- 
treated cells or cells treated for increasing periods of 
time with HU and ara-C. The levels of vimentin RNA 
were barely detectable in untreated cells, but greatly in- 
duced by HU and ara-C (fig.2). This increase was first 
observed at 24 h and reached a m~imum at 48 h. 
To exclude a non-specific stimulatory action of HU 
and ara-C on transcription, we also measured the levels 
of other RNAs, namely c-myc, ODC and #-actin. The 
drugs reduced the levels of c-myc and ODC transcripts, 
the reduction being more rapid and intense in the case 
of HU. The levels of @actin RNA were unaffected ex- 
cept for a slight decrease at the end (72 and 96 h) of the 
treatment (fig.2). These results suggest hat vimentin 
transcription in U-937 cells is specifically stimulated by 
S-phase inhibitors. 
3.3, rnd~cti~~ of vime~ti~ protein levels 
Finally, we found it of interest o analyze whether the 
induction of vimentin at the mRNA level by HU and 
ara-C is also reflected at the protein level. This was car- 
ried out using two different experimental approaches. 
First, the total cellular vimentin content was measured 
by immunoblot assays using whole extracts from either 
untreated cells or cells treated for increasing periods of 
time with HU and ara-C. The vimentin content was 
below detectable levels in untreated cells, but it increas- 
_ - 
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l Control 0 TPA Q HU B ara-C 
Fig.1. Expression of cetl surface antigens in U-937 cells. Untreated (control) cells and cells treated with TPA (3 x lo-* M), HU (3 x IO-” Mf or 
ara-C (lo-’ M) for the indicated times were incubated with the MAbs Bear/l (anti-CDllb), HCl/i (anti-CDilc) or FG1/6 (anti-TfR). The 
percentage of cells expressing the antigens was determined by indirect immunofluorescence combined with flow cytometry. Data represent he 
average of three experiments. 
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Fig.4. Changes in cytoskeleton-associated vimentin content. 
Following formaldehyde fixation, Triton X-100 permeabilization and 
incubation with an anti-vimentin antibody, the vimentin content in 
the cells was determined by indirect immunofluorescence combined 
with flow cytometry. Dotted lines: untreated cells. Continuous lines: 
drug-treated cells. The dotted, vertical lines, delimit the regions 
corresponding to non-specific fluorescence (-) which were given by the 
distribution of cells incubated only with the second antibody (FITC- 
labelied anti-IgG). Results of one of two similar experiments. 
t3-actin 
Fig.2. Changes in the levels of specific mRNAs. Total cytoplasmic 
RNA was extracted from untreated cells (a) and from cells treated for 
6 h (b) 24 h (c), 48 h (d), 72 h(e) and 96 h (f) with either HU or ara-C. 
RNA blots (15 /rg per lane) were prepared and hybridized sequentially 
with the indicated probes. The faint band at the top on vimentin 
hybridization represents non-specific hybridization of 28s ribosomal 
RNA. Results of one of two similar experiments. 
ed to reach readily measurable levels in drug-treated 
cells (fig.3). In a second experimental approach, the 
vimentin content was measured by indirect im- 
munofluorescence combined with flow cytometry. The 
vimentin was made accessible to specific antibodies by 
formaldehyde fixation followed by Triton 
kDa a b c d e 
66- , 
HU 
Fig.3. Changes in total vimentin content. Whole lysates were obtained 
from untreated cells (a) and from cells treated for 24 h (b), 48 (c), 72 
h (d) and 96 h (e) with either HU or ara-C. Extracts corresponding to 
150 /~g of total protein were separated by SDS-PAGE, transferred 
onto nitrocellulose and assayed for reactivity with an anti-vimentin 
antibody. The reaction was developed using cr-chloronaphtol as 
substrate. Only the region containing the vimentin band is shown in 
the figure. Results of one of two similar experiments. 
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permeabilization of the cells. Thus, the fluorescent 
values reflect the fraction of non-extractable, 
cytoskeleton-associated vimentin. Treatment with HU 
and ara-C produced an increase in the fluorescence in- 
tensity in relation to untreated cells, demonstrating that 
the drugs effectively augment the vimentin in the 
cytoskeleton (fig.4). 
4. DISCUSSION 
The results presented here show that treatment with 
S-phase inhibitors triggers the phenotypic differentia- 
tion of human promono~~ic leukemia U-937 cells. This 
was evidenced, firstly, by the induction by HU and ara- 
C of two surface differentiation-specific markers, 
namely the CDllb and CDllc antigens, with an effi- 
ciently similar to that obtained with the potent matura- 
tion inducer TPA. Another evidence at the molecular 
level is provided by the decrease of c-myc mRNA levels 
upon drug treatment, since differentiation induction of 
myeloid cells seems to be associated with down- 
regulation of c-myc expression (see [20,21] for reviews). 
In fact, c-myc expression decreases rapidly upon treat- 
ment with typical maturation inducers, such as TPA, 
DMSO or dibuty~l cyclic AMP [5,22,23]. On the con- 
trary, HU does not inhibit c-myc expression in the 
absence of cell differentiation [24]. 
In addition, our results show that treatment with S- 
phase inhibitors greatly induces the expression of the 
vimentin gene in U-937 cells, both at the mRNA and 
protein levels. It must be noted: (i) that this effect is 
produced by two compounds, HU and ara-C, which in- 
hibit DNA synthesis through different action 
mechanisms; and (ii) that none of these compounds 
modified vimentin expression when used as growth in- 
hibitors in non-differentiating cell systems ([ZS] and un- 
published observations). This suggests that vimentin in- 
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Volume 259, number 1 FEBS LETTERS December 1989 
duction in U-937 cells is neither a mere consequence of 
cell growth inhibition nor a side effect of a particular 
drug, but instead it is related to the differentiation pro- 
cess. Earlier observations indicated that TPA induces 
vimentin expression in myeloid cells [1,2,5]. Never- 
theless this agent also causes a transient activation of 
other genes, including ODC (5) and @actin [26]. In con- 
trast, the action of HU and ara-C seems to be more 
specific, since only vimentin and not the other genes ex- 
amined by us were activated. 
In summary, it appears that S-phase inhibitors trigger 
the phenotypic differentiation of U-937 cells, and that 
vimentin induction is probably implicated in this pro- 
cess. Whether it is an absolute requirement or not, as 
well as the exact role of vimentin expression in the 
maturation process, remains to be determined. 
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